Add Basal Insulin to Dulaglutide
With a fasting glucose of 180 mg/dL after one month of dulaglutide 1.5 mg, you should add basal insulin to the regimen rather than waiting longer or switching therapies. 1
Rationale for Adding Basal Insulin
The 2025 ADA Standards of Care provide clear guidance for this exact scenario. When A1C remains above goal on a GLP-1 receptor agonist, the next step is to add basal insulin rather than uptitrating the GLP-1 RA or switching agents 1. A fasting glucose of 180 mg/dL indicates inadequate basal glucose control that requires insulin intervention.
Specific Initiation Protocol
Start basal insulin using this approach: 1
- Initial dose: 10 units daily OR 0.1-0.2 units/kg per day
- Timing: Bedtime administration (if using NPH) or once daily (if using basal analog)
- Target: Set individualized fasting plasma glucose goal (typically 80-130 mg/dL for most adults)
- Titration algorithm: Increase by 2 units every 3 days until fasting glucose reaches target without hypoglycemia
Choice of Basal Insulin
Select basal insulin based on cost and patient-specific factors 1. Options include:
- Basal insulin analogs (preferred for lower hypoglycemia risk)
- NPH insulin (cost-effective alternative)
Critical point: Prescribe glucagon for emergency hypoglycemia when initiating insulin 1.
Why Not Wait Longer on Dulaglutide Alone?
While dulaglutide demonstrates glucose-lowering effects within 24 hours of the first dose 2, and early fasting glucose at week 2 can predict later response 3, a fasting glucose of 180 mg/dL after one month indicates insufficient response. Research shows that baseline HbA1c is the strongest predictor of dulaglutide response 4, and patients with elevated fasting glucose specifically benefit from adding basal insulin rather than relying solely on GLP-1 RA therapy 5.
Monitoring and Adjustment
Reassess at every visit: 1
- If hypoglycemia occurs without clear cause, reduce insulin dose by 10-20%
- Continue dulaglutide—the combination of GLP-1 RA plus basal insulin is evidence-based and may be available as fixed-ratio products
- Avoid therapeutic inertia by reassessing every 3-6 months
Common Pitfall to Avoid
Do not discontinue dulaglutide when adding insulin. The guideline explicitly recommends continuing GLP-1 RA therapy when adding basal insulin, as the mechanisms are complementary 1. Dulaglutide addresses postprandial glucose and provides weight benefits, while basal insulin specifically targets fasting hyperglycemia—exactly what this patient needs.